PDCD1 and lung carcinoma: Recently, checkpoint inhibitor antibodies against PD1 (Nivolumab and Pembrolizumab) or PD-L1 (Duvalumab, Atezolizumab, and Avelumab) have been used to treat lung cancer patients with an overall response rate of approximately 20–25% [3].